UPDATE: Piper Jaffray Lowers PT on CONMED

A report from Piper Jaffray reiterates its Neutral rating and lowers its price target from $32 to $31 on CONMED

. The report states, “Our primary question at the moment pertains to when the company's revenue growth rate can return to the mid- to upper single digits. If management can achieve anything in that range, we feel the ConMED's operating model is poised to deliver substantial leverage. We remain Neutral rating on CNMD for now, trimming our price target from $32 to $31 due to slightly lower estimates and group valuations." CNMD closed yesterday at $26.48.